AngioDynamics Beats Q1 Earnings Estimates on Strong Med Tech Sales

Key Facts

1AngioDynamics beat first-quarter earnings estimates as revenues rose 6.9% year-over-year.

2Growth was driven by strong Med Tech performance, specifically robust sales of Auryon and NanoKnife products.

AngioDynamics beat first-quarter earnings estimates as revenues rose 6.9% year-over-year. Zacks reported that the growth was driven by strong performance in the Med Tech segment, specifically robust sales of Auryon and NanoKnife products.

ANGO closed at $11.23 on October 8, 2026, after reaching a day high of $13.8 and a low of $11.06 during the session. The results highlight margin expansion and strong demand for the company's specialized medical technology platforms.